secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-004989
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma confirms FY2024 revenue guidance met at J.P. Morgan conference
--------------------------------------------------------------------------

- Company expects to meet previously announced total, neuroscience and oncology revenue guidance for year ended Dec 31, 2024.
- Outlook disclosed at J.P. Morgan Healthcare Conference on Jan 14, 2025.
- No specific revenue or EPS figures provided; guidance ranges unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525004989/0001193125-25-004989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525004989/d699726d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer